# US 2023/0310577 A1 · Removal of agglomerates

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0310577 A1
- Document ID: US20230310577A1
- Status: Published application
- Kind: A1
- Application number: 18/161,210
- Filed: 2023-01-30
- Published: 2023-10-05
- Earliest claimed: 2018-07-10
- Assignees: Seqirus Pty Ltd
- Applicants: Seqirus Pty Ltd
- Inventors: Steven ROCKMAN; Jesse BODLE; Nancy GUZZO-PERNELL
- Web page: https://patentgrep.com/patent/US20230310577A1

## CPC

- A61K 39/12: Viral antigens
- A61K 39/145: Orthomyxoviridae, e.g. influenza virus
- B01J 19/10: employing sonic or ultrasonic vibrations
- C12N 13/00: Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves
- A61K 2039/5252: {inactivated (killed)}
- A61K 2039/70: {Multivalent vaccine}
- C12N 2760/16134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2760/16234: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- B01J: CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present disclosure provides a method of dispersing agglomerated material in a preparation comprising influenza proteins. The method comprises subjecting the preparation to sonication.

## Claims

### Claim at position 1

1-15. (canceled)

### Claim 16

A preparation comprising influenza proteins, wherein the preparation has been subjected to sonication to disperse agglomerated material, wherein the sonication is conducted at a rate of 80% amplitude.

### Claim 17 (depends on 16)

The preparation according to claim 16, wherein the preparation comprises influenza haemagglutinin.

### Claim 18 (depends on 16)

The preparation according to claim 16, wherein the preparation comprises split influenza virions.

### Claim 19 (depends on 18)

The preparation according to claim 18, wherein the preparation comprises a level of less than 0.02% of detergent.

### Claim 20 (depends on 16)

The preparation according to claim 16, wherein the sonication is conducted for a time and at intensity to disperse at least 50% of agglomerates present in the preparation.

### Claim 21 (depends on 16)

The preparation according to claim 16, wherein the sonication is conducted to transfer at least 90 Joules/mL of energy.

### Claim 22 (depends on 16)

The preparation according to claim 16, wherein H3N2 strains that have a predicted HA glycosylation site probability score (pGly score) ≥16 require sonication of ≥90 Joules/mL and H1N1 strains that have a pGly score ≥11 require sonication of ≥90 Joules/mL.

### Claim 23

An influenza vaccine, the vaccine comprising a preparation comprising inactivated or split influenza virions, wherein the preparation has been subjected to sonication and wherein the sonication is conducted at a rate of 80% amplitude.

### Claim 24 (depends on 23)

The influenza vaccine according to claim 23, wherein the vaccine comprises at least 3 different influenza strains.

### Claim 25 (depends on 23)

The influenza vaccine according to claim 23, wherein the vaccine is a monovalent vaccine or a quadrivalent vaccine.

### Claim 26 (depends on 23)

The influenza vaccine according to claim 23, wherein the vaccine comprises influenza A and influenza B.

### Claim 27 (depends on 23)

The influenza vaccine according to claim 23, wherein the vaccine is substantially free of agglomerated material.

### Claim 28

A preparation comprising influenza proteins, wherein the preparation has been subjected to sonication to disperse agglomerated material, wherein the sonication is conducted to transfer at least 90 Joules/mL of energy.

### Claim 29 (depends on 28)

The preparation according to claim 28, wherein the preparation comprises inactivated or split influenza virions from at least 3 different influenza strains.

### Claim 30 (depends on 28)

The preparation according to claim 28, wherein the preparation is a monovalent vaccine or a quadrivalent vaccine.

### Claim 31 (depends on 28)

The preparation according to claim 28, wherein the preparation comprises influenza A and influenza B.

### Claim 32

A preparation comprising influenza proteins, wherein the preparation has been subjected to sonication; wherein H3N2 strains that have a predicted HA glycosylation site probability score (pGly score) Z 16 require sonication of Z 90 Joules/mL and H1N1 strains that have a pGly score Z 11 require sonication of Z 90 Joules/mL.

### Claim 33 (depends on 32)

The preparation according to claim 32, wherein the preparation comprises inactivated or split influenza virions from at least 3 different influenza strains.

### Claim 34 (depends on 32)

The preparation according to claim 32, wherein the preparation is a monovalent vaccine or a quadrivalent vaccine.

### Claim 35 (depends on 32)

The preparation according to claim 32, wherein the preparation comprises influenza A and influenza B.
